{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:36:32Z","timestamp":1794540992657,"version":"4.9.1"},"reference-count":207,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of hematologic malignancies by enabling antigen-specific tumor targeting and durable clinical responses. However, its translation to solid tumors has been limited by fundamental biological barriers, including antigen heterogeneity, poor tumor infiltration, and profound immunosuppressive and metabolic constraints within the tumor microenvironment. These factors collectively drive CAR-T cell dysfunction, exhaustion, and limited persistence, resulting in modest and inconsistent clinical efficacy. This review provides a concept-driven synthesis of recent advances in CAR-T cell therapy for solid tumors, with a specific focus on systems-level engineering strategies that integrate tumor biology, spatial context, and cellular metabolism. We highlight emerging approaches such as\n                    <jats:italic>in vivo<\/jats:italic>\n                    CAR programming, logic-gated and multi-antigen receptor designs, and armored CAR-T cells engineered to resist immunosuppression and metabolic stress. Importantly, this review goes beyond descriptive engineering advances by emphasizing the growing role of computational modeling, artificial intelligence, and spatial multi-omics in guiding antigen selection, CAR circuit design, and predictive assessment of therapeutic responses. Unlike prior reviews that primarily summarize antigen targets or CAR engineering strategies, this review integrates biological barriers in solid tumors with emerging engineering solutions to provide a conceptual framework for the development and clinical translation of next-generation CAR-T therapies. By integrating biological determinants of failure with rational engineering solutions, the review delineates translational pathways that link mechanistic insight to clinical implementation. This review advances the field by framing CAR-T therapy for solid tumors as a systems engineering challenge rather than a single-target optimization problem. By integrating immunology, bioengineering, computational sciences, and spatial biology, we outline a roadmap for the development of safer, more durable, and context-aware CAR-T therapies. Continued progress will depend on tumor-specific antigen discovery, interdisciplinary collaboration, and scalable manufacturing and regulatory frameworks, collectively enabling the next generation of effective CAR-T therapies for solid tumors.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1796675","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T05:43:03Z","timestamp":1775022183000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["CAR-T cells in solid tumors: engineering, biomarkers, translational pathways and the road ahead"],"prefix":"10.3389","volume":"17","author":[{"given":"Nada Saed Homod","family":"Al Shaer","sequence":"first","affiliation":[{"name":"College of Medicine, Alfaisal University","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibraheem","family":"Masoud","sequence":"additional","affiliation":[{"name":"College of Medicine, Alfaisal University","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Tleyjeh","sequence":"additional","affiliation":[{"name":"College of Medicine, Alfaisal University","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attas Alawi","family":"Al-Attas","sequence":"additional","affiliation":[{"name":"College of Medicine, Alfaisal University","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam Alawi","family":"Al-Attas","sequence":"additional","affiliation":[{"name":"College of Medicine, Alfaisal University","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Imran","family":"Khan","sequence":"additional","affiliation":[{"name":"College of Medicine, Alfaisal University","place":["Riyadh, Saudi Arabia"]},{"name":"King Faisal Specialist Hospital and Research Center","place":["Jeddah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Yaqinuddin","sequence":"additional","affiliation":[{"name":"College of Medicine, Alfaisal University","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(87)90502-X","article-title":"Expression of chimeric receptor composed of immunoglobulin-derived V resions and T-cell receptor-derived C regions","volume":"149","author":"Kuwana","year":"1987","journal-title":"Biochem Biophys Res Commun"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e21776","article-title":"CAR-T cell therapy for hematological Malignancies: History, status and promise","volume":"9","author":"Wang","year":"2023","journal-title":"Heliyon"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicenter, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicenter seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: the history and progress of CAR T cell therapy","volume":"14","author":"Mitra","year":"2023","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.687822","article-title":"Obstacles and coping strategies of CAR-T cell immunotherapy in solid tumors","volume":"12","author":"Miao","year":"2021","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0759-3","article-title":"Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.14405","article-title":"New strategies for the treatment of solid tumors with CAR-T cells","volume":"12","author":"Zhang","year":"2016","journal-title":"Int J Biol Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/cells14050320","article-title":"Strategies to overcome antigen heterogeneity in CAR-T cell therapy","volume":"14","author":"Zhang","year":"2025","journal-title":"Cells"},{"key":"B12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri.2017.145","article-title":"Improving immune\u2013vascular crosstalk for cancer immunotherapy","volume":"18","author":"Huang","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41419-023-06110-6","article-title":"Stromal cells in the tumor microenvironment: accomplices of tumor progression","volume":"14","author":"Zhao","year":"2023","journal-title":"Cell Death Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-1683","article-title":"Next-generation CAR T-cell therapies","volume":"12","author":"Young","year":"2022","journal-title":"Cancer Discov"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02250","article-title":"Engineered T cell therapy for cancer in the clinic","volume":"10","author":"Zhao","year":"2019","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30172-3","article-title":"Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy","volume":"6","author":"Rashdan","year":"2018","journal-title":"Lancet Respir Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.17","article-title":"Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity","volume":"21","author":"Lamers","year":"2013","journal-title":"Mol Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12935-024-03315-3","article-title":"Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors","volume":"24","author":"Chen","year":"2024","journal-title":"Cancer Cell Int"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nature10762","article-title":"Clonal evolution in cancer","volume":"481","author":"Greaves","year":"2012","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40164-022-00277-y","article-title":"Heterogeneity of the tumor immune microenvironment and its clinical relevance","volume":"11","author":"Jia","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13045-021-01103-4","article-title":"Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response","volume":"14","author":"Fu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1013117","article-title":"Spatiotemporal dynamics of tumor\u2013CAR T-cell interaction following local administration in solid cancers","volume":"21","author":"Owens","year":"2025","journal-title":"PloS Comput Biol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1063\/5.0207941","article-title":"CAR T cell infiltration and cytotoxic killing within the core of 3D breast cancer spheroids under the control of antigen sensing in microwell arrays","volume":"8","author":"Cho","year":"2024","journal-title":"APL Bioeng"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1321596","article-title":"Fine-tuning the antigen sensitivity of CAR T cells: emerging strategies and current challenges","volume":"14","author":"Harrer","year":"2023","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117252","article-title":"Antigen escape in CAR-T cell therapy: mechanisms and overcoming strategies","volume":"178","author":"Lin","year":"2024","journal-title":"Biomedicine Pharmacotherapy"},{"key":"B29","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives","volume":"20","author":"Mao","year":"2021","journal-title":"Mol Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0007-1","article-title":"Targeting the tumor stroma to improve cancer therapy","volume":"15","author":"Valkenburg","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2019.00086","article-title":"The role of the extracellular matrix in cancer stemness","volume":"7","author":"Nallanthighal","year":"2019","journal-title":"Front Cell Dev Biol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0002","article-title":"The interplay between extracellular matrix remodeling and cancer therapeutics","volume":"14","author":"Prakash","year":"2024","journal-title":"Cancer Discov"},{"key":"B33","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1172\/JCI45817","article-title":"Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors","volume":"122","author":"Salmon","year":"2012","journal-title":"J Clin Invest"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102353","article-title":"CAR-T cells in solid tumors: challenges and breakthroughs","volume":"6","author":"Escobar","year":"2025","journal-title":"Cell Rep Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13287-020-02128-1","article-title":"CAR T cells in solid tumors: challenges and opportunities","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"B36","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-024-02047-2","article-title":"Deciphering the tumor immune microenvironment from a multidimensional omics perspective: insight into next-generation CAR-T cell immunotherapy and beyond","volume":"23","author":"Zhou","year":"2024","journal-title":"Mol Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1648987","article-title":"Multi-omics analysis of the tumor microenvironment after metastasis: advancing toward personalized immunotherapy and molecular targeted strategies","volume":"16","author":"Gao","year":"2025","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/ph18010075","article-title":"Leveraging single-cell multi-omics to decode tumor microenvironment diversity and therapeutic resistance","volume":"18","author":"Sabit","year":"2025","journal-title":"Pharmaceuticals"},{"key":"B39","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s12943-025-02426-3","article-title":"Single-cell multi-omics in cancer immunotherapy: from tumor heterogeneity to personalized precision treatment","volume":"24","author":"Le","year":"2025","journal-title":"Mol Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101740","article-title":"The spatial multi-omics revolution in cancer therapy: precision redefined","volume":"5","author":"Du","year":"2024","journal-title":"Cell Rep Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.996721","article-title":"A review of spatial profiling technologies for characterizing the tumor microenvironment in immuno-oncology","volume":"13","author":"Hu","year":"2022","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-019-03351-7","article-title":"Tumor angiogenesis: causes, consequences, challenges and opportunities","volume":"77","author":"Lugano","year":"2020","journal-title":"Cell Mol Life Sci"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10092292","article-title":"The interplay of tumor vessels and immune cells affects immunotherapy of glioblastoma","volume":"10","author":"Ghosh","year":"2022","journal-title":"Biomedicines"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2024.102510","article-title":"Chemokines that govern T cell activity in tumors","volume":"92","author":"Mempel","year":"2025","journal-title":"Curr Opin Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41417-021-00303-x","article-title":"Key chemokines direct migration of immune cells in solid tumors","volume":"29","author":"Kohli","year":"2022","journal-title":"Cancer Gene Ther"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-0618","article-title":"Ccl22 diverts T regulatory cells and controls the growth of melanoma","volume":"76","author":"Klarquist","year":"2016","journal-title":"Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/cells7080108","article-title":"Chemokine receptors and exercise to tackle the inadequacy of T cell homing to the tumor site","volume":"7","author":"Idorn","year":"2018","journal-title":"Cells"},{"key":"B48","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12943-025-02386-8","article-title":"Advancing CAR-based cell therapies for solid tumors: challenges, therapeutic strategies, and perspectives","volume":"24","author":"Azeez","year":"2025","journal-title":"Mol Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a041170","article-title":"Mechanisms regulating T cell\u2013endothelial cell interactions","volume":"12","author":"Alcaide","year":"2022","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200324270","article-title":"Endothelial expression of PD\u2010L1 and PD\u2010L2 down\u2010regulates CD8 + T cell activation and cytolysis","volume":"33","author":"Rodig","year":"2003","journal-title":"Eur J Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701155","article-title":"Chimeric antigen receptor T cell therapy: Challenges to bench-to-bedside efficacy","volume":"200","author":"Srivastava","year":"2018","journal-title":"J Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-2458","article-title":"Trafficking of T cells into tumors","volume":"74","author":"Slaney","year":"2014","journal-title":"Cancer Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/cells11223626","article-title":"Tumor microenvironment immunosuppression: A roadblock to CAR T-cell advancement in solid tumors","volume":"11","author":"Cheever","year":"2022","journal-title":"Cells"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2016.01.043","article-title":"Tumor microenvironment and therapeutic response","volume":"387","author":"Wu","year":"2017","journal-title":"Cancer Lett"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.692142","article-title":"Tumor-induced inflammatory cytokines and the emerging diagnostic devices for cancer detection and prognosis","volume":"11","author":"Kartikasari","year":"2021","journal-title":"Front Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3390\/cells9030561","article-title":"Myeloid-derived suppressor cells as a therapeutic target for cancer","volume":"9","author":"Law","year":"2020","journal-title":"Cells"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-010-0855-8","article-title":"Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity","volume":"59","author":"Ostrand-Rosenberg","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0426","article-title":"A phase I\/IIa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia","volume":"24","author":"Enblad","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.155.3.1151","article-title":"Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases","volume":"155","author":"Sakaguchi","year":"1995","journal-title":"J Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/ni1428","article-title":"Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice","volume":"8","author":"Kim","year":"2007","journal-title":"Nat Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.06.053","article-title":"Foxp3 exploits a pre-existent enhancer landscape for regulatory T cell lineage specification","volume":"151","author":"Samstein","year":"2012","journal-title":"Cell"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.5.2756","article-title":"Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma","volume":"169","author":"Liyanage","year":"2002","journal-title":"J Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1244","article-title":"The expression of the regulatory T cell\u2013specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer","volume":"11","author":"Wolf","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.25016","article-title":"Treg(s) in cancer: Friends or foe","volume":"230","author":"Wolf","year":"2015","journal-title":"J Cell Physiol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3687","article-title":"T-regulatory cells: Key players in tumor immune escape and angiogenesis","volume":"72","author":"Facciabene","year":"2012","journal-title":"Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/nri1457","article-title":"Ido expression by dendritic cells: tolerance and tryptophan catabolism","volume":"4","author":"Mellor","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.12.033","article-title":"Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia","volume":"29","author":"Cox","year":"2021","journal-title":"Mol Ther"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701041","article-title":"Metabolic barriers to T cell function in tumors","volume":"200","author":"Sugiura","year":"2018","journal-title":"J Immunol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12943-019-1089-9","article-title":"Role of hypoxia in cancer therapy by regulating the tumor microenvironment","volume":"18","author":"Jing","year":"2019","journal-title":"Mol Cancer"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa1260","article-title":"Immunological mechanisms of the antitumor effects of supplemental oxygenation","volume":"7","author":"Hatfield","year":"2015","journal-title":"Sci Transl Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02358","article-title":"Hypoxia modifies the transcriptome of human NK cells, modulates their immunoregulatory profile, and influences NK cell subset migration","volume":"9","author":"Parodi","year":"2018","journal-title":"Front Immunol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/mco2.6","article-title":"Metabolism in tumor microenvironment: Implications for cancer immunotherapy","volume":"1","author":"Shi","year":"2020","journal-title":"MedComm (Beijing)"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.77","article-title":"Tumor acidosis: from the passenger to the driver\u2019s seat","volume":"17","author":"Corbet","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2016.08.011","article-title":"LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells","volume":"24","author":"Brand","year":"2016","journal-title":"Cell Metab"},{"key":"B75","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.canlet.2020.12.021","article-title":"The oncogenic and clinical implications of lactate induced immunosuppression in the tumor microenvironment","volume":"500","author":"Hayes","year":"2021","journal-title":"Cancer Lett"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.cmet.2016.12.018","article-title":"Foxp3 reprograms T cell metabolism to function in low-glucose, high-lactate environments","volume":"25","author":"Angelin","year":"2017","journal-title":"Cell Metab"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/nature13490","article-title":"Functional polarization of tumor-associated macrophages by tumor-derived lactic acid","volume":"513","author":"Colegio","year":"2014","journal-title":"Nature"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.08.012","article-title":"Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses","volume":"162","author":"Ho","year":"2015","journal-title":"Cell"},{"key":"B80","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/j.celrep.2019.04.022","article-title":"Acetate promotes T cell effector function during glucose restriction","volume":"27","author":"Qiu","year":"2019","journal-title":"Cell Rep"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0184-6","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00128","article-title":"CAR T cells for solid tumors: New strategies for finding, infiltrating, and surviving in the tumor microenvironment","volume":"10","author":"Martinez","year":"2019","journal-title":"Front Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3390\/biom15101407","article-title":"Advancing CAR-T therapy for solid tumors: From barriers to clinical progress","volume":"15","author":"Smirnov","year":"2025","journal-title":"Biomolecules"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189162","article-title":"T cell exhaustion in human cancers","volume":"1879","author":"Kang","year":"2024","journal-title":"Biochim Biophys Acta (BBA) - Rev Cancer"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-00834-9","article-title":"Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion","volume":"22","author":"Scharping","year":"2021","journal-title":"Nat Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0793-3","article-title":"Disturbed mitochondrial dynamics in CD8+ TILs reinforce T cell exhaustion","volume":"21","author":"Yu","year":"2020","journal-title":"Nat Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0725-2","article-title":"Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen","volume":"21","author":"Vardhana","year":"2020","journal-title":"Nat Immunol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"6692","DOI":"10.1038\/ncomms7692","article-title":"PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation","volume":"6","author":"Patsoukis","year":"2015","journal-title":"Nat Commun"},{"key":"B89","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s40425-019-0628-7","article-title":"PD-1 signaling affects cristae morphology and leads to mitochondrial dysfunction in human CD8+ T lymphocytes","volume":"7","author":"Ogando","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402180","article-title":"Programmed death-1 controls T cell survival by regulating oxidative metabolism","volume":"194","author":"Tkachev","year":"2015","journal-title":"J Immunol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2009.00767.x","article-title":"PD\u20101 signaling in primary T cells","volume":"229","author":"Riley","year":"2009","journal-title":"Immunol Rev"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1093\/oxfimm\/iqad006","article-title":"The current state and future of T-cell exhaustion research","volume":"4","author":"Jenkins","year":"2023","journal-title":"Oxf Open Immunol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/19.17.4783","article-title":"Gene expression elicited by NFAT in the presence or absence of cooperative recruitment of Fos and Jun","volume":"19","author":"Macian","year":"2000","journal-title":"EMBO J"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.7.4832","article-title":"NFATc1 regulates PD-1 expression upon T cell activation","volume":"181","author":"Oestreich","year":"2008","journal-title":"J Immunol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.01.006","article-title":"The transcription factor NFAT promotes exhaustion of activated CD8 + T cells","volume":"42","author":"Martinez","year":"2015","journal-title":"Immunity"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.immuni.2017.11.021","article-title":"Transcription factor IRF4 promotes CD8+ T cell exhaustion and limits the development of memory-like T cells during chronic infection","volume":"47","author":"Man","year":"2017","journal-title":"Immunity"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2232","article-title":"Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF","volume":"16","author":"Quigley","year":"2010","journal-title":"Nat Med"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-0985-x","article-title":"NR4A transcription factors limit CAR T cell function in solid tumors","volume":"567","author":"Chen","year":"2019","journal-title":"Nature"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2046","article-title":"Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection","volume":"12","author":"Kao","year":"2011","journal-title":"Nat Immunol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109120","article-title":"Role of nuclear localization in the regulation and function of T-bet and Eomes in exhausted CD8 T cells","volume":"35","author":"McLane","year":"2021","journal-title":"Cell Rep"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1126\/science.1229620","article-title":"Progenitor and terminal subsets of CD8 + T cells cooperate to contain chronic viral infection","volume":"338","author":"Paley","year":"2012","journal-title":"Sci (1979)"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.07.021","article-title":"T cell factor 1-expressing memory-like CD8+ T cells sustain the immune response to chronic viral infections","volume":"45","author":"Utzschneider","year":"2016","journal-title":"Immunity"},{"key":"B103","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.immuni.2019.09.013","article-title":"TCF-1-centered transcriptional network drives an effector versus exhausted CD8 T cell-fate decision","volume":"51","author":"Chen","year":"2019","journal-title":"Immunity"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.08.021","article-title":"Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory","volume":"37","author":"Doering","year":"2012","journal-title":"Immunity"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1325-x","article-title":"TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion","volume":"571","author":"Khan","year":"2019","journal-title":"Nature"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1905675116","article-title":"TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8 + T cell exhaustion","volume":"116","author":"Seo","year":"2019","journal-title":"Proc Natl Acad Sci"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1324-y","article-title":"TOX is a critical regulator of tumor-specific T cell differentiation","volume":"571","author":"Scott","year":"2019","journal-title":"Nature"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1326-9","article-title":"TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection","volume":"571","author":"Alfei","year":"2019","journal-title":"Nature"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0403-4","article-title":"Single-cell RNA-seq reveals TOX as a key regulator of CD8+ T cell persistence in chronic infection","volume":"20","author":"Yao","year":"2019","journal-title":"Nat Immunol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2024.05.007","article-title":"Future perspectives on engineered T cells for cancer","volume":"10","author":"Posey","year":"2024","journal-title":"Trends Cancer"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.780399","article-title":"Implementing logic gates for safer immunotherapy of cancer","volume":"12","author":"Savanur","year":"2021","journal-title":"Front Immunol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0101","article-title":"Programming CAR T cell tumor recognition: Tuned antigen sensing and logic gating","volume":"13","author":"Hamieh","year":"2023","journal-title":"Cancer Discov"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010208","article-title":"Integrating binding affinity and tonic signaling enables a rational CAR design for augmented T cell function","volume":"12","author":"Barden","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010702","article-title":"Tailoring CAR surface density and dynamics to improve CAR-T cell therapy","volume":"13","author":"Hinckley-Boned","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1490911","article-title":"Logic-gated and contextual control of immunotherapy for solid tumors: Contrasting multi-specific T cell engagers and CAR-T cell therapies","volume":"15","author":"Nolan-Stevaux","year":"2024","journal-title":"Front Immunol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1227\/neuprac.0000000000000170","article-title":"Departments of neurosurgery are leaders in highly cited glioblastoma research","volume":"6","author":"Tazhibi","year":"2025","journal-title":"Neurosurg Pract"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abe7378","article-title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","volume":"13","author":"Choe","year":"2021","journal-title":"Sci Transl Med"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.3390\/cancers9070092","article-title":"Regional delivery of chimeric antigen receptor (CAR) T-cells for cancer therapy","volume":"9","author":"Sridhar","year":"2017","journal-title":"Cancers (Basel)"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2022.100870","article-title":"Locoregional CAR T cells for children with CNS tumors: Clinical procedure and catheter safety","volume":"36","author":"Vitanza","year":"2023","journal-title":"Neoplasia"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2023.10.007","article-title":"Intraperitoneal administration of carcinoembryonic antigen-directed chimeric antigen receptor T cells is a robust delivery route for effective treatment of peritoneal carcinomatosis from colorectal cancer in pre-clinical study","volume":"26","author":"Qian","year":"2024","journal-title":"Cytotherapy"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008275","article-title":"CARs are sharpening their weapons","volume":"12","author":"Pievani","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1643941","article-title":"Current strategies for armoring chimeric antigen receptor T-cells to overcome barriers of the solid tumor microenvironment","volume":"16","author":"Yang","year":"2025","journal-title":"Front Immunol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0293","article-title":"Glypican-3\u2013specific CAR T cells coexpressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma","volume":"8","author":"Batra","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.2565","article-title":"Rewiring T-cell responses to soluble factors with chimeric antigen receptors","volume":"14","author":"Chang","year":"2018","journal-title":"Nat Chem Biol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-023-01830-x","article-title":"Target delivery of a PD-1-TREM2 scFv by CAR-T cells enhances anti-tumor efficacy in colorectal cancer","volume":"22","author":"Chen","year":"2023","journal-title":"Mol Cancer"},{"key":"B127","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-12-822620-9.00021-5","article-title":"Chimeric antigen receptor-modified cells for the treatment of solid tumors: First steps in a thousand-mile march","volume-title":"NK Cells in Cancer Immunotherapy: Successes and Challenges","author":"Rafei","year":"2023"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymben.2024.10.009","article-title":"Applying metabolic control strategies to engineered T cell cancer therapies","volume":"86","author":"Fox","year":"2024","journal-title":"Metab Eng"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008272","article-title":"Engineering amino acid uptake or catabolism promotes CAR T-cell adaption to the tumor environment","volume":"7","author":"Panetti","year":"2023","journal-title":"Blood Adv"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004500","article-title":"Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity","volume":"136","author":"Fultang","year":"2020","journal-title":"Blood"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.05.006","article-title":"GLUT1 overexpression enhances CAR T cell metabolic fitness and anti-tumor efficacy","volume":"32","author":"Shi","year":"2024","journal-title":"Mol Ther"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-017-0002-2","article-title":"A Pck1-directed glycogen metabolic program regulates formation and maintenance of memory CD8+ T cells","volume":"20","author":"Ma","year":"2018","journal-title":"Nat Cell Biol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.cmet.2021.02.015","article-title":"CD36-mediated ferroptosis dampens intratumoral CD8+ T cell effector function and impairs their antitumor ability","volume":"33","author":"Ma","year":"2021","journal-title":"Cell Metab"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2020.01.008","article-title":"Inhibition of cholesterol esterification enzyme enhances the potency of human chimeric antigen receptor T cells against pancreatic carcinoma","volume":"16","author":"Zhao","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1389971","article-title":"The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: A systematic review","volume":"15","author":"Satapathy","year":"2024","journal-title":"Front Immunol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1455163","article-title":"Oncolytic virus and CAR-T cell therapy in solid tumors","volume":"15","author":"Ponterio","year":"2024","journal-title":"Front Immunol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1460266","article-title":"Targeting TGF\u03b2 with chimeric switch receptor and secreted trap to improve T cells anti-tumor activity","volume":"15","author":"Matikhina","year":"2024","journal-title":"Front Immunol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.720692","article-title":"Chimeric antigen receptor-T cells: A pharmaceutical scope","volume":"12","author":"Hern\u00e1ndez-L\u00f3pez","year":"2021","journal-title":"Front Pharmacol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1378944","article-title":"Biomarkers for prediction of CAR T therapy outcomes: Current and future perspectives","volume":"15","author":"Levstek","year":"2024","journal-title":"Front Immunol"},{"key":"B140","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s44178-025-00205-0","article-title":"Breaking barriers: The emerging promise of CAR-T cell therapy in solid tumors","volume":"4","author":"Nie","year":"2025","journal-title":"Holistic Integr Oncol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1101\/2024.06.11.24308741","article-title":"Large scale in-house point-of-care manufacturing of clinical grade autologous anti-CD19 CAR T cells in Saudi Arabia","author":"Warda","year":"2024"},{"key":"B142","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41434-023-00425-x","article-title":"A practical approach for adoption of a hub and spoke model for cell and gene therapies in low- and middle-income countries: Framework and case studies","volume":"31","author":"Saleh","year":"2024","journal-title":"Gene Ther"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1583116","article-title":"CAR-T cell therapy clinical trials: Global progress, challenges, and future directions from ClinicalTrials.gov insights","volume":"16","author":"Cao","year":"2025","journal-title":"Front Immunol"},{"key":"B144","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s43046-024-00240-4","article-title":"Practical immunomodulatory landscape of glioblastoma multiforme (GBM) therapy","volume":"36","author":"Norollahi","year":"2024","journal-title":"J Egypt Natl Canc Inst"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2025.2001","article-title":"CAR-T in relapsed refractory high-grade glioma and glioblastoma \u2013 who, what, when and how","volume":"19","author":"Parekh","year":"2025","journal-title":"Ecancermedicalscience"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-473440","article-title":"Autologous T-cell therapies in solid tumor Malignancies: Current landscape and future opportunities","volume":"45","author":"Reinhorn","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.3390\/cells13010101","article-title":"Chimeric antigen receptor T cell therapy for pancreatic cancer: A review of current evidence","volume":"13","author":"Czaplicka","year":"2024","journal-title":"Cells"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04547-4","article-title":"Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: A path moving forward or a dead end","volume":"149","author":"Drougkas","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2338984","article-title":"Global research trends in CAR-T cell therapy for solid tumors: A comprehensive visualization and bibliometric study (2012\u20132023)","volume":"20","author":"Miao","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1638186","article-title":"Breaking barriers: Enhancing CAR-armored T cell therapy for solid tumors through microenvironment remodeling","volume":"16","author":"Andreou","year":"2025","journal-title":"Front Immunol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1440169","article-title":"CD133-directed CAR T cells for advanced metastasis Malignancies: a phase I trial","volume":"7","author":"Wang","year":"2018","journal-title":"Oncoimmunology"},{"key":"B152","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40164-024-00495-6","article-title":"Cytokine-based models for efficient differentiation between infection and cytokine release syndrome in patients with hematological Malignancies","volume":"13","author":"Wang","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20221988","article-title":"Self-regulating CAR-T cells modulate cytokine release syndrome in adoptive T-cell therapy","volume":"221","author":"Lin","year":"2024","journal-title":"J Exp Med"},{"key":"B154","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2275457","article-title":"Building safety into CAR-T therapy","volume":"19","author":"Peters","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1600403","article-title":"CAR T cell therapy for central nervous system solid tumors: current progress and future directions","volume":"16","author":"Kaminskiy","year":"2025","journal-title":"Front Immunol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1165576","article-title":"Biomaterials promote in vivo generation and immunotherapy of CAR-T cells","volume":"14","author":"Qin","year":"2023","journal-title":"Front Immunol"},{"key":"B159","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40164-024-00542-2","article-title":"Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers","volume":"13","author":"Gu","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2016.11.014","article-title":"EUS-guided fine-needle injection of gemcitabine for locally advanced and metastatic pancreatic cancer","volume":"86","author":"Levy","year":"2017","journal-title":"Gastrointest Endosc"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2014.50","article-title":"Neutrophil:lymphocyte ratios and serum cytokine changes after hepatic artery chimeric antigen receptor-modified T-cell infusions for liver metastases","volume":"21","author":"Saied","year":"2014","journal-title":"Cancer Gene Ther"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2024.100739","article-title":"Armoring chimeric antigen receptor (CAR) T cells as micropharmacies for cancer therapy","volume":"24","author":"Carcopino","year":"2024","journal-title":"Immuno-Oncology Technol"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1409021","article-title":"Charting new paradigms for CAR-T cell therapy beyond current Achilles heels","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-21-0084","article-title":"Scalable manufacturing of CAR T cells for cancer immunotherapy","volume":"2","author":"Abou-el-Enein","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.34172\/apb.2024.034","article-title":"The Art of Bioimmunogenomics (BIGs) 5.0 in CAR-T cell therapy for lymphoma management","volume":"14","author":"Anurogo","year":"2024","journal-title":"Adv Pharm Bull"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17172898","article-title":"Advancing CAR T-cell therapy in solid tumors: current landscape and future directions","volume":"17","author":"Rafii","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B167","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13287-024-03783-4","article-title":"CAR-T cell-derived exosomes: a new perspective for cancer therapy","volume":"15","author":"Sani","year":"2024","journal-title":"Stem Cell Res Ther"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041003","article-title":"Systematic review on CAR-T cell clinical trials up to 2022: academic center input","volume":"15","author":"Wang","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.31547\/bct-2023-023","article-title":"Challenges in global access to CAR-T cells: an Asian perspective","volume":"7","author":"Hwang","year":"2024","journal-title":"Blood Cell Ther"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105266","article-title":"Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment","volume":"106","author":"Bui","year":"2024","journal-title":"EBioMedicine"},{"key":"B171","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13045-025-01745-8","article-title":"Genome-edited allogeneic CAR-T cells: the next generation of cancer immunotherapies","volume":"18","author":"Su","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102209","article-title":"Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in vivo CAR-T therapy for inflammaging","volume":"6","author":"Zhang","year":"2025","journal-title":"Cell Rep Med"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2017.254","article-title":"CAR T cells in trials: recent achievements and challenges that remain in the production of modified T cells for clinical applications","volume":"29","author":"K\u00f6hl","year":"2018","journal-title":"Hum Gene Ther"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"B175","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13059-017-1215-1","article-title":"Multi-omics approaches to disease","volume":"18","author":"Hasin","year":"2017","journal-title":"Genome Biol"},{"key":"B176","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.cell.2020.03.039","article-title":"Pooled knockin targeting for genome engineering of cellular immunotherapies","volume":"181","author":"Roth","year":"2020","journal-title":"Cell"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1677","article-title":"Integrative bulk and single-cell profiling of premanufacture T-cell populations reveals factors mediating long-term persistence of CAR T-cell therapy","volume":"11","author":"Chen","year":"2021","journal-title":"Cancer Discov"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-00449-x","article-title":"Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy","volume":"18","author":"Gohil","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B179","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.gpb.2021.02.004","article-title":"Single-cell analysis technologies for immuno-oncology research: from mechanistic delineation to biomarker discovery","volume":"19","author":"Bai","year":"2021","journal-title":"Genomics Proteomics Bioinf"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00729-2","article-title":"Advancing CAR T cell therapy through the use of multidimensional omics data","volume":"20","author":"Yang","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-022-00515-3","article-title":"The emerging landscape of spatial profiling technologies","volume":"23","author":"Moffitt","year":"2022","journal-title":"Nat Rev Genet"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biodatasci-020422-050645","article-title":"Single-cell multiomics","volume":"6","author":"Flynn","year":"2023","journal-title":"Annu Rev BioMed Data Sci"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrep.2023.101589","article-title":"Advancements and applications of single-cell multi-omics techniques in cancer research: unveiling heterogeneity and paving the way for precision therapeutics","volume":"37","author":"Liang","year":"2024","journal-title":"Biochem Biophys Rep"},{"key":"B185","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12943-024-02050-7","article-title":"Unbiasedly decoding the tumor microenvironment with single-cell multiomics analysis in pancreatic cancer","volume":"23","author":"Fu","year":"2024","journal-title":"Mol Cancer"},{"key":"B186","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1038\/s41467-023-37353-8","article-title":"Pan-cancer classification of single cells in the tumor microenvironment","volume":"14","author":"Nofech-Mozes","year":"2023","journal-title":"Nat Commun"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02371-y","article-title":"Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance","volume":"29","author":"Chu","year":"2023","journal-title":"Nat Med"},{"key":"B188","doi-asserted-by":"publisher","first-page":"6619","DOI":"10.1038\/s41467-022-34395-2","article-title":"Pan-cancer single-cell analysis reveals the heterogeneity and plasticity of cancer-associated fibroblasts in the tumor microenvironment","volume":"13","author":"Luo","year":"2022","journal-title":"Nat Commun"},{"key":"B189","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s12967-023-04292-3","article-title":"Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments","volume":"21","author":"Dagar","year":"2023","journal-title":"J Transl Med"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1676112","article-title":"Applications of artificial intelligence in cancer immunotherapy: a frontier review on enhancing treatment efficacy and safety","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.3390\/cells11193165","article-title":"Investigating two modes of cancer-associated antigen heterogeneity in an agent-based model of chimeric antigen receptor T-cell therapy","volume":"11","author":"Giorgadze","year":"2022","journal-title":"Cells"},{"key":"B192","doi-asserted-by":"publisher","first-page":"12307","DOI":"10.1038\/s41598-024-63125-5","article-title":"In silico study of heterogeneous tumour-derived organoid response to CAR T-cell therapy","volume":"14","author":"Luque","year":"2024","journal-title":"Sci Rep"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-01686-y","article-title":"Single-cell mapping of combinatorial target antigens for CAR switches using logic gates","volume":"41","author":"Kwon","year":"2023","journal-title":"Nat Biotechnol"},{"key":"B194","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41746-025-01967-7","article-title":"Machine learning analysis reveals tumor heterogeneity and stromal-immune niches in breast cancer","volume":"8","author":"Kuang","year":"2025","journal-title":"NPJ Digit Med"},{"key":"B195","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/03007995.2025.2502125","article-title":"Epidemiology and approaches for management of relapsed and refractory multiple myeloma in Gulf Countries: a narrative review and insights from the Gulf multiple myeloma experts","volume":"41","author":"Alhuraiji","year":"2025","journal-title":"Curr Med Res Opin"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1462307","article-title":"The current socioeconomic and regulatory landscape of immune effector cell therapies","volume":"11","author":"Sainatham","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"B197","doi-asserted-by":"crossref","DOI":"10.5772\/intechopen.1005116","article-title":"Recent updates on chimeric antigen receptor T-cell approaches in cancer immunotherapy","volume-title":"Advances in Cancer Immunotherapy","author":"Sahlolbei","year":"2024"},{"key":"B198","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/0008-5472.CAN-09-2587","article-title":"Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine","volume":"70","author":"Srivastava","year":"2010","journal-title":"Cancer Res"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03745-0","article-title":"Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13R\u03b12 in recurrent glioblastoma: a phase 1 trial","volume":"31","author":"Bagley","year":"2025","journal-title":"Nat Med"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"N Engl J Med"},{"key":"B201","doi-asserted-by":"publisher","first-page":"3541\u2013","DOI":"10.1200\/JCO.2025.43.16_suppl.3541","article-title":"Safety and efficacy of anti-CEA CAR-T cells to prolong relapse-free survival of colorectal cancer liver metastases patients after radical resection","volume":"43","author":"Zhang","year":"2025","journal-title":"J Clin Oncol"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-017-0440-4","article-title":"Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers","volume":"9","author":"Feng","year":"2018","journal-title":"Protein Cell"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00860-8","article-title":"Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician\u2019s choice for previously treated advanced gastric or gastro-esophageal junction cancer (CT041-ST-01): a randomized, open-label, phase 2 trial","volume":"405","author":"Qi","year":"2025","journal-title":"Lancet"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3259","article-title":"Chimeric antigen receptor-Glypican-3 T-cell therapy for advanced hepatocellular carcinoma: Results of phase I trials","volume":"26","author":"Shi","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02979-8","article-title":"PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"30","author":"Dorff","year":"2024","journal-title":"Nat Med"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF\u03b2-insensitive armored CAR T\u2009cells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat Med"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with Malignant pleural disease, in combination with the anti\u2013PD-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1796675\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T05:43:06Z","timestamp":1775022186000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1796675\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":207,"alternative-id":["10.3389\/fimmu.2026.1796675"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1796675","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"article-number":"1796675"}}